Hikma Pharmaceuticals (LON:HIK) Shares Cross Above 200 Day Moving Average – Here’s What Happened

Hikma Pharmaceuticals PLC (LON:HIK) shares passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of GBX 1,444.83 and traded as high as GBX 1,541. Hikma Pharmaceuticals shares last traded at GBX 1,540, with a volume of 1,728,501 shares traded.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on HIK. Berenberg Bank reissued a “buy” rating and set a GBX 1,800 price objective on shares of Hikma Pharmaceuticals in a research note on Tuesday, April 28th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a GBX 195 price objective on shares of Hikma Pharmaceuticals in a research note on Monday, June 22nd. Finally, Jefferies Financial Group lifted their target price on Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of GBX 1,687.

Hikma Pharmaceuticals Stock Performance

The stock has a market capitalization of £3.24 billion, a PE ratio of 8.42, a PEG ratio of 2.38 and a beta of 0.65. The business’s 50 day moving average is GBX 1,450.71 and its 200 day moving average is GBX 1,444.73. The company has a current ratio of 1.82, a quick ratio of 1.27 and a debt-to-equity ratio of 61.84.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.